Video
Why Research Assessing Dapagliflozin Advanced From Cardiorenal Effects to Prevention, Organ Protection
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.
Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
During the discussion, Kosiborod explained why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
